Volume 73, Issue 6 p. 963-969
Brief Report

HLA–B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti–Carbamylated Protein Antibody–Positive/Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis

Cristina Regueiro

Cristina Regueiro

Instituto de Investigacion Sanitaria and Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

Search for more papers by this author
Desire Casares-Marfil

Desire Casares-Marfil

Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain

Search for more papers by this author
Karin Lundberg

Karin Lundberg

Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Search for more papers by this author
Rachel Knevel

Rachel Knevel

Leiden University Medical Center, Leiden, The Netherlands, and Brigham and Women’s Hospital, Boston, Massachusetts

Search for more papers by this author
Marialbert Acosta-Herrera

Marialbert Acosta-Herrera

Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain

Search for more papers by this author
Luis Rodriguez-Rodriguez

Luis Rodriguez-Rodriguez

Hospital Clínico San Carlos, Instituto Investigación Sanitaria San Carlos, Madrid, Spain

Search for more papers by this author
Raquel Lopez-Mejias

Raquel Lopez-Mejias

Valdecilla Biomedical Research Institute, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Search for more papers by this author
Eva Perez-Pampin

Eva Perez-Pampin

Instituto de Investigacion Sanitaria and Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

Search for more papers by this author
Ana Triguero-Martinez

Ana Triguero-Martinez

Instituto de Investigación Sanitaria la Princesa and Hospital Universitario de la Princesa, Madrid, Spain

Search for more papers by this author
Laura Nuño

Laura Nuño

Instituto de Investigación del Hospital Universitario La Paz, Madrid, Spain

Search for more papers by this author
Ivan Ferraz-Amaro

Ivan Ferraz-Amaro

Hospital Universitario de Canarias, Tenerife, Spain

Search for more papers by this author
Javier Rodriguez-Carrio

Javier Rodriguez-Carrio

University of Oviedo, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Oviedo, Spain

Search for more papers by this author
Rosario Lopez-Pedrera

Rosario Lopez-Pedrera

Maimonides Institute for Research in Biomedicine of Cordoba, Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain

Search for more papers by this author
Montse Robustillo-Villarino

Montse Robustillo-Villarino

Hospital Universitario Doctor Peset, Valencia, Spain

Search for more papers by this author
Santos Castañeda

Santos Castañeda

Instituto de Investigación Sanitaria la Princesa and Hospital Universitario de la Princesa, Madrid, Spain

Search for more papers by this author
Sara Remuzgo-Martinez

Sara Remuzgo-Martinez

Valdecilla Biomedical Research Institute, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Search for more papers by this author
Mercedes Alperi

Mercedes Alperi

Hospital Universitario Central de Asturias, and Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain

Search for more papers by this author
Juan J. Alegre-Sancho

Juan J. Alegre-Sancho

Hospital Universitario Doctor Peset, Valencia, Spain

Search for more papers by this author
Alejandro Balsa

Alejandro Balsa

Instituto de Investigación del Hospital Universitario La Paz, Madrid, Spain

Search for more papers by this author
Isidoro Gonzalez-Alvaro

Isidoro Gonzalez-Alvaro

Instituto de Investigación Sanitaria la Princesa and Hospital Universitario de la Princesa, Madrid, Spain

Search for more papers by this author
Antonio Mera

Antonio Mera

Instituto de Investigacion Sanitaria and Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

Search for more papers by this author
Benjamin Fernandez-Gutierrez

Benjamin Fernandez-Gutierrez

Hospital Clínico San Carlos, Instituto Investigación Sanitaria San Carlos, Madrid, Spain

Search for more papers by this author
Miguel A. Gonzalez-Gay

Miguel A. Gonzalez-Gay

Valdecilla Biomedical Research Institute, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Search for more papers by this author
Leendert A. Trouw

Leendert A. Trouw

Leiden University Medical Center, Leiden, The Netherlands

Search for more papers by this author
Caroline Grönwall

Caroline Grönwall

Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Search for more papers by this author
Leonid Padyukov

Leonid Padyukov

Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Search for more papers by this author
Javier Martin

Javier Martin

Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain

Search for more papers by this author
Antonio Gonzalez

Corresponding Author

Antonio Gonzalez

Instituto de Investigacion Sanitaria and Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

Address correspondence to Antonio Gonzalez, MD, PhD, Hospital Clínico Universitario de Santiago, Travesia de Choupana, 15706 Santiago de Compostela, A Coruña, Spain. Email: [email protected].

Search for more papers by this author
First published: 31 December 2020
Citations: 8
Supported in part by the Instituto de Salud Carlos III (grant PI16/00113 to Dr. Rodriguez-Carrio, grant RD16/0012/0015 to Dr. Lopez-Pedrera, grant RD16/0012/0012 to Dr. Balsa, grant RD16/0012/0011 to Dr. Gonzalez-Alvaro, grant RD16/0012/0004 to Dr. Fernandez-Gutierrez, grant RD16/0012/0009 to Dr. Gonzalez-Gay, grant RD16/0012/0013 to Dr. Martin, and grants PI17/01606 and RD16/0012/0014 to Dr. Gonzalez), which are partially financed by the European Regional Development Fund of the EU (FEDER), and by the Innovative Medicines Initiative (BTCure grant 831434). Dr. Regueiro’s work was supported by Ministerio de Educacion Cultura y Deporte (grant FPU15/03434). Dr. Acosta-Herrera’s work was supported by a Juan de la Cierva Fellowship (grant IJC2018-035131-I).
Ms Regueiro and Ms Casares-Marfil contributed equally to this work. Drs. Martin and Gonzalez contributed equally to this work.
Dr. Balsa has received consulting fees, speaking fees, and/or honoraria from AbbVie, Pfizer, Novartis, Bristol Myers Squibb, Nordic, Sanofi, Sandoz, UCB, and Lilly (less than $10,000 each) and research support from AbbVie, Pfizer, Novartis, Bristol Myers Squibb, Nordic, and Sanofi. Dr. Gonzalez-Alvaro has received consulting fees, speaking fees, and/or honoraria from Lilly, Sanofi, Bristol Myers Squibb, AbbVie, and Roche Laboratories (less than $10,000 each). Dr. Gonzalez-Gay has received consulting fees, speaking fees, and/or honoraria from AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene, Sobi and MSD (less than $10,000 each) and research support from AbbVie, MSD, Jansen, and Roche. Dr. Trouw is a coinventor on the patent EP2671078B1 relating to the detection of anti-CarP antibodies. Dr. Gonzalez has received speaking fees from Bristol Myers Squibb (less than $10,000) and research support from Bristol Myers Squibb. No other disclosures relevant to this article were reported.

Abstract

Objective

Previously, only the HLA–DRB1 alleles have been assessed in rheumatoid arthritis (RA). The aim of the present study was to identify the key major histocompatibility complex (MHC) susceptibility factors showing a significant association with anti–carbamylated protein antibody–positive (anti-CarP+) RA.

Methods

Analyses were restricted to RA patients who were anti–cyclic citrullinated peptide antibody negative (anti-CCP−), because the anti-CCP status dominated the results otherwise. Therefore, we studied samples from 1,821 anti-CCP− RA patients and 6,821 population controls from Spain, Sweden, and the Netherlands. The genotypes for ~8,000 MHC biallelic variants were assessed by dense genotyping and imputation. Their association with the anti-CarP status in RA patients was tested with logistic regression and combined with inverse-variance meta-analysis. Significance of the associations was assessed according to a study-specific threshold of P < 2.0 × 10−5.

Results

The HLA–B*08 allele and its correlated amino acid variant Asp-9 showed a significant association with anti-CarP+/anti-CCP− RA (P < 3.78 × 10−7; I2 = 0). This association was specific when assessed relative to 3 comparator groups: population controls, anti-CarP−/anti-CCP− RA patients, and anti-CCP− RA patients who were positive for other anti–citrullinated protein antibodies. Based on these findings, anti-CarP+/anti-CCP− RA patients could be separated from other antibody-defined subsets of RA patients in whom an association with the HLA–B*08 allele has been previously demonstrated. No other MHC variant remained associated with anti-CarP+/anti-CCP− RA after accounting for the presence of the HLA–B*08 allele. Specifically, the reported association of HLA–DRB1*03 was observed at a level comparable to that reported previously, but it was attributable to linkage disequilibrium.

Conclusion

These results identify HLA–B*08 carrying Asp-9 as the MHC locus showing the strongest association with anti-CarP+/anti-CCP− RA. This knowledge may help clarify the role of the HLA in susceptibility to specific subsets of RA, by shaping the spectrum of RA autoantibodies.